PPA
HRTX icon

Parametric Portfolio Associates’s Heron Therapeutics HRTX Stock Holding History

Parametric Portfolio Associates’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$1.24M Buy
216,477
+41,299
+24% +$302K ﹤0.01% 2681
2021
Q4 		$1.6M Sell
175,178
-2,594
-1% -$26.5K ﹤0.01% 2577
2021
Q3 		$1.9M Buy
177,772
+17,440
+11% +$212K ﹤0.01% 2468
2021
Q2 		$2.49M Buy
160,332
+29,643
+23% +$472K ﹤0.01% 2312
2021
Q1 		$2.12M Buy
130,689
+38,574
+42% +$688K ﹤0.01% 2743
2020
Q4 		$1.95M Buy
92,115
+19,369
+27% +$337K ﹤0.01% 2668
2020
Q3 		$1.08M Sell
72,746
-499
-0.7% -$7.79K ﹤0.01% 2881
2020
Q2 		$1.08M Buy
73,245
+4,834
+7% +$79.4K ﹤0.01% 2887
2020
Q1 		$803K Sell
68,411
-45,549
-40% -$856K ﹤0.01% 2915
2019
Q4 		$2.68M Buy
113,960
+16,863
+17% +$373K ﹤0.01% 2497
2019
Q3 		$1.8M Buy
97,097
+39,223
+68% +$722K ﹤0.01% 2698
2019
Q2 		$1.08M Buy
57,874
+17,186
+42% +$343K ﹤0.01% 3016
2019
Q1 		$994K Buy
40,688
+3,176
+8% +$83.1K ﹤0.01% 3031
2018
Q4 		$973K Sell
37,512
-33,643
-47% -$925K ﹤0.01% 2993
2018
Q3 		$2.25M Sell
71,155
-35,280
-33% -$1.31M ﹤0.01% 2628
2018
Q2 		$4.13M Sell
106,435
-6,047
-5% -$193K ﹤0.01% 2124
2018
Q1 		$3.1M Buy
112,482
+56,643
+101% +$1.28M ﹤0.01% 2285
2017
Q4 		$1.01M Buy
55,839
+10,749
+24% +$175K ﹤0.01% 3019
2017
Q3 		$728K Buy
45,090
+11,218
+33% +$176K ﹤0.01% 3213
2017
Q2 		$469K Buy
33,872
+733
+2% +$10.6K ﹤0.01% 3401
2017
Q1 		$497K Buy
33,139
+15,394
+87% +$213K ﹤0.01% 3205
2016
Q4 		$232K Sell
17,745
-3,102
-15% -$48.7K ﹤0.01% 3538
2016
Q3 		$359K Buy
20,847
+9,029
+76% +$168K ﹤0.01% 3338
2016
Q2 		$213K Buy
+11,818
New +$231K ﹤0.01% 3585
2016
Q1 		– Sell
-49,894
Closed -$1.33M – 4004
2015
Q4 		$1.33M Buy
49,894
+24,517
+97% +$656K ﹤0.01% 2559
2015
Q3 		$619K Buy
25,377
+15,865
+167% +$529K ﹤0.01% 2608
2015
Q2 		$296K Buy
+9,512
New +$179K ﹤0.01% 3581

Other funds holding HRTX

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

Parametric Portfolio Associates's HRTX Position: Q1 2022 in Review

Parametric Portfolio Associates increased its Heron Therapeutics (HRTX) stake by 24% in Q1 2022, buying an estimated $302K and bringing the position to 216,477 shares worth $1.24M. The position accounts for ﹤0.01% of the portfolio, ranked #2681.

Parametric Portfolio Associates first reported a position in HRTX in Q2 2015 and has held it in 27 quarters since. The position peaked at $4.13M in Q2 2018. 187 funds tracked by Wall St. Rank hold HRTX as of Q1 2022.

  • Parametric Portfolio Associates held 216,477 shares of Heron Therapeutics worth $1.24M as of Q1 2022.
  • Parametric Portfolio Associates bought 41,299 Heron Therapeutics shares in Q1 2022, an estimated $302K.
  • Heron Therapeutics made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #2681 holding.
  • Parametric Portfolio Associates first reported a position in Heron Therapeutics in Q2 2015 and has held it in 27 quarters since.
  • Parametric Portfolio Associates's Heron Therapeutics position peaked at $4.13M in Q2 2018.
  • 187 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.